How should the dosing of ceftazidime‑avibactam be adjusted for renal impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ceftazidime-Avibactam Renal Dose Adjustment

For patients with renal impairment, ceftazidime-avibactam requires dose reduction based on creatinine clearance (CrCL), with the standard dose of 2.5 g IV every 8 hours adjusted to lower doses and/or extended intervals as renal function declines. 1

Standard Dosing by Renal Function

The FDA-approved dosing adjustments for ceftazidime-avibactam are based on estimated CrCL using the Cockcroft-Gault equation 1:

Dosing Table

  • CrCL >50 mL/min: 2.5 g (2 g ceftazidime/0.5 g avibactam) IV every 8 hours
  • CrCL 31-50 mL/min: 1.25 g IV every 8 hours
  • CrCL 16-30 mL/min: 0.94 g IV every 12 hours
  • CrCL 6-15 mL/min: 0.94 g IV every 24 hours
  • CrCL ≤5 mL/min: 0.94 g IV every 48 hours

Hemodialysis Patients

For patients on hemodialysis, administer ceftazidime-avibactam after each dialysis session on dialysis days 1. Both ceftazidime and avibactam are removed by hemodialysis, necessitating post-dialysis dosing to maintain therapeutic levels.

Clinical Guidelines Support

Recent guidelines consistently recommend ceftazidime-avibactam 2.5 g IV every 8 hours for carbapenem-resistant Enterobacterales (CRE) infections in patients with normal renal function 2. These guidelines emphasize the importance of appropriate renal dose adjustment but do not provide detailed alternative regimens beyond the FDA recommendations.

Critical Considerations for Severe Infections

Extended Infusion Strategy

For critically ill patients or those with severe infections, consider extending the infusion time to 3 hours rather than the standard 2 hours, particularly when treating organisms with higher MICs 2, 3. This approach optimizes the time that drug concentrations remain above the MIC, which is the key pharmacodynamic driver for β-lactam efficacy.

Augmented Renal Clearance

In critically ill patients with augmented renal clearance (CrCL >130 mL/min), standard dosing may result in subtherapeutic levels. Recent research suggests these patients may require higher doses or continuous infusion to achieve adequate exposure 4, 5.

Risk of Underdosing in Renal Impairment

A critical caveat: Recent observational data indicate that renal-adjusted doses may be associated with higher mortality in bloodstream infections caused by KPC-producing organisms 6. This suggests that the recommended dose reductions, while preventing toxicity, may provide inadequate drug exposure for severe infections. In patients with renal impairment and life-threatening infections, therapeutic drug monitoring should be strongly considered to ensure adequate exposure while avoiding neurotoxicity.

Neurotoxicity Risk

Ceftazidime accumulation in renal impairment can lead to serious neurological complications including seizures, encephalopathy, and myoclonus 1. The risk increases when trough concentrations exceed 80-104 mg/L 7. Monitor patients with renal impairment closely for neurological symptoms, particularly confusion, altered mental status, or involuntary movements, and reduce the dose or extend the interval if these occur.

Practical Implementation

Initial Dosing

  1. Calculate CrCL using the Cockcroft-Gault equation with actual body weight
  2. Select the appropriate dose from the table above
  3. Administer as a 2-hour IV infusion (extend to 3 hours for severe infections or high MIC organisms)

Monitoring

  • Reassess renal function every 48-72 hours in critically ill patients, as acute kidney injury or recovery can necessitate dose adjustment
  • For patients on continuous renal replacement therapy (CRRT), standard dosing may result in excessive drug accumulation; consider dose reduction and therapeutic drug monitoring 7
  • In hemodialysis patients, ensure dosing occurs after dialysis sessions to prevent premature drug removal

Special Populations

Patients with fluctuating renal function: When renal function is improving or worsening rapidly, err on the side of the more conservative (lower) dose initially, then adjust based on clinical response and repeat CrCL measurements within 24-48 hours.

CRRT patients: The standard every-8-hour regimen may cause excessive exposure. Consider 1.25-2.5 g every 12 hours depending on CRRT modality and effluent rate, with therapeutic drug monitoring if available 7.

Related Questions

What is the appropriate ceftazidime‑avibactam dosing for a patient with a creatinine clearance of about 3 mL/min (severe renal impairment)?
What are the recommended dosing adjustments of ceftazidime‑avibactam in adult patients with normal renal function, moderate, mild‑to‑moderate, or severe renal impairment, including those on intermittent hemodialysis?
What is the appropriate dosing regimen of Zerbaxa (ceftazidime‑avibactam) for a 76‑year‑old male, weighing 95 kg, height 180 cm, with impaired renal function (serum creatinine 134 µmol/L) after spine fracture surgery, who is currently receiving piperacillin‑tazobactam (Tazocin) empirically?
What is the appropriate ceftazidime‑avibactam dosing for a patient with chronic kidney disease stage 3b (estimated creatinine clearance 30–44 mL/min)?
What are the indications, dosing regimen, and renal dose adjustments for ceftazidime‑avibactam in adults and pediatric patients?
How should steroids be tapered in a patient with Cushing's disease who underwent pituitary surgery, with a day‑1 cortisol of 20 nmol/L, now on day 3 receiving hydrocortisone 50 mg three times daily?
What antibiotics are appropriate for a multi‑resistant Enterobacter cloacae infection?
What is the recommended management, including complement‑C5 inhibition, for a non‑diabetic patient in his early 30s with BMI 20, severe hypertension, atypical arteriosclerosis, recurrent stage 1 acute kidney injury associated with chronic hemoglobinuria and an abnormal complement panel?
Is it appropriate to taper hydrocortisone to 20 mg three times daily today and then 20 mg, 10 mg, and 10 mg tomorrow in a patient three days after pituitary surgery with a day‑1 cortisol of 20 nmol/L who is currently receiving hydrocortisone 50 mg three times daily?
Should azithromycin (Azee) be given together with the rest of the antitubercular therapy (ATT) for non‑tuberculous mycobacterial (NTM) management?
Can you interpret the left hip and cervical spine imaging for an 83‑year‑old woman with chronic left hip pain, left‑sided neck pain, a history of breast cancer, back arthritis, recent dizziness, and concerns about osteoarthritis versus metastatic disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.